Next-gen Injectable (C-005)

About Giant Biogene

Founded in 2015 and publicly listed in Hong Kong, Giant Biogene has established itself as a dominant force in biomaterial-based medical beauty through its proprietary human-like recombinant collagen platform. The company executes a dual-strategy, commercializing its technology via a portfolio of premium functional skincare brands and a suite of medical-grade devices for professional use. With a market capitalization of ~$29.4B, it is a standout success story, translating advanced biotech innovation into scalable commercial products for the Chinese and global markets.

Therapeutic Areas